Symbols / LGND Stock $231.27 +1.22% Ligand Pharmaceuticals Incorporated

Healthcare • Biotechnology • United States • NGM
LGND (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Todd C. Davis Ph.D.
Exch · Country NGM · United States
Market Cap 4.63B
Enterprise Value 4.33B
Income 124.45M
Sales 268.09M
FCF (ttm) 87.09M
Book/sh 51.44
Cash/sh 36.78
Employees 47
Insider 10d —
IPO Nov 18, 1992
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 37.73
Forward P/E 23.28
PEG 1.53
P/S 17.29
P/B 4.50
P/C —
EV/EBITDA 53.47
EV/Sales 16.15
Quick Ratio 21.83
Current Ratio 22.23
Debt/Eq 44.39
LT Debt/Eq —
EPS (ttm) 6.13
EPS next Y 9.93
EPS Growth —
Revenue Growth 39.40%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-26
ROA 2.36%
ROE 13.47%
ROIC —
Gross Margin 64.29%
Oper. Margin 33.59%
Profit Margin 46.42%
Shs Outstand 20.04M
Shs Float 19.47M
Insider Own 2.39%
Instit Own 105.24%
Short Float 8.49%
Short Ratio 5.62
Short Interest 1.41M
52W High 238.31
vs 52W High -2.95%
52W Low 98.89
vs 52W Low 133.87%
Beta 1.00
Impl. Vol. 50.96%
Rel Volume 0.70
Avg Volume 214.77K
Volume 149.64K
Target (mean) $246.70
Tgt Median $246.50
Tgt Low $220.00
Tgt High $282.00
# Analysts 10
Recom Strong_buy
Prev Close $228.48
Price $231.27
Change 1.22%
About

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$246.70
Mean price target
2. Current target
$231.27
Latest analyst target
3. DCF / Fair value
$78.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$231.27
Low
$220.00
High
$282.00
Mean
$246.70

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-15 main Citigroup Buy → Buy $282
2026-04-14 main HC Wainwright & Co. Buy → Buy $243
2026-03-24 main Citigroup Buy → Buy $276
2026-03-11 init B of A Securities — → Buy $244
2026-02-27 main Oppenheimer Outperform → Outperform $277
2026-02-24 main HC Wainwright & Co. Buy → Buy $239
2025-12-10 main RBC Capital Outperform → Outperform $235
2025-12-10 main Stifel Buy → Buy $230
2025-12-09 init Citigroup — → Buy $270
2025-11-10 main RBC Capital Outperform → Outperform $234
2025-11-07 main Benchmark Buy → Buy $220
2025-11-07 main Oppenheimer Outperform → Outperform $275
2025-11-06 main HC Wainwright & Co. Buy → Buy $231
2025-11-03 main Oppenheimer Outperform → Outperform $250
2025-09-03 main Oppenheimer Outperform → Outperform $190
2025-09-02 main Benchmark Buy → Buy $175
2025-08-28 main HC Wainwright & Co. Buy → Buy $206
2025-08-08 main RBC Capital Outperform → Outperform $185
2025-08-07 main Oppenheimer Outperform → Outperform $167
2025-07-30 main Oppenheimer Outperform → Outperform $162
News
RSS: Latest LGND news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 KOZARICH JOHN W. Director — 467 $199.97 $94,440
2026-04-01 REARDON ANDREW THOMAS Officer — 5,000 $198.85 $1,006,224
2026-04-01 REARDON ANDREW THOMAS Officer — 5,000 $52.27 $261,350
2026-03-23 SABBA STEPHEN L. Director — 1,000 $207.87 $207,873
2026-03-11 ESPINOZA OCTAVIO Chief Financial Officer — 3,057 $225.00 $687,825
2026-03-11 ESPINOZA OCTAVIO Chief Financial Officer — 2,405 $92.65 $222,823
2026-03-06 LAMATTINA JOHN L Director — 2,161 $200.76 $433,842
2026-03-06 LAMATTINA JOHN L Director — 2,161 $114.15 $246,678
2026-03-04 ESPINOZA OCTAVIO Chief Financial Officer — 13,423 $198.71 $2,762,822
2026-03-04 ESPINOZA OCTAVIO Chief Financial Officer — 2,073 $58.49 $131,609
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
268.09
+60.40%
167.13
+27.28%
131.31
-33.09%
196.25
Operating Revenue
268.09
+60.40%
167.13
+27.28%
131.31
-33.09%
196.25
Cost Of Revenue
14.55
+31.38%
11.07
+5.35%
10.51
-80.10%
52.83
Reconciled Cost Of Revenue
13.48
+53.31%
8.79
+15.03%
7.64
-78.48%
35.53
Gross Profit
253.54
+62.46%
156.06
+29.19%
120.80
-15.77%
143.42
Operating Expense
206.34
+55.10%
133.04
+19.87%
110.98
-20.94%
140.38
Research And Development
81.18
+278.91%
21.43
-12.68%
24.54
-32.00%
36.08
Selling General And Administration
92.45
+17.54%
78.65
+48.99%
52.79
-24.65%
70.06
General And Administrative Expense
92.45
+17.54%
78.65
+48.99%
52.79
-24.65%
70.06
Other Gand A
92.45
+17.54%
78.65
+48.99%
52.79
-24.65%
70.06
Other Operating Expenses
—
—
—
—
Total Expenses
220.89
+53.28%
144.11
+18.62%
121.49
-37.12%
193.21
Operating Income
47.20
+105.03%
23.02
+134.41%
9.82
+223.38%
3.04
Total Operating Income As Reported
41.00
+281.38%
-22.61
-289.30%
11.94
+293.22%
3.04
EBITDA
197.45
+384.02%
40.79
-59.54%
100.84
+12.86%
89.34
Normalized EBITDA
94.54
+105.54%
46.00
-12.14%
52.35
-13.90%
60.80
Reconciled Depreciation
33.77
-4.15%
35.24
-3.51%
36.52
-29.13%
51.53
EBIT
163.68
+2846.44%
5.55
-91.36%
64.32
+70.10%
37.81
Total Unusual Items
102.91
+2077.44%
-5.20
-110.73%
48.49
+69.89%
28.54
Total Unusual Items Excluding Goodwill
102.91
+2077.44%
-5.20
-110.73%
48.49
+69.89%
28.54
Special Income Charges
-6.20
+79.73%
-30.57
-1541.40%
2.12
0.00
Write Off
6.20
-79.73%
30.57
0.00
0.00
Net Income
124.45
+3186.63%
-4.03
-107.73%
52.15
+256.33%
-33.36
Pretax Income
158.96
+6212.95%
2.52
-96.04%
63.66
+76.78%
36.01
Net Non Operating Interest Income Expense
8.94
+78.24%
5.02
-28.87%
7.05
+2756.28%
0.25
Interest Expense Non Operating
4.71
+55.25%
3.04
+362.96%
0.66
-63.54%
1.80
Net Interest Income
8.94
+78.24%
5.02
-28.87%
7.05
+2756.28%
0.25
Interest Expense
4.71
+55.25%
3.04
+362.96%
0.66
-63.54%
1.80
Interest Income Non Operating
13.66
+69.57%
8.05
+4.46%
7.71
+276.88%
2.05
Interest Income
13.66
+69.57%
8.05
+4.46%
7.71
+276.88%
2.05
Other Income Expense
102.82
+502.87%
-25.52
-154.55%
46.78
+42.95%
32.73
Other Non Operating Income Expenses
-0.09
+99.56%
-20.32
-1093.71%
-1.70
-140.65%
4.19
Gain On Sale Of Security
109.10
+330.08%
25.37
-45.29%
46.37
+62.46%
28.54
Gain On Sale Of Business
0.00
0.00
-100.00%
2.12
0.00
Tax Provision
34.51
+426.82%
6.55
-33.44%
9.84
-76.13%
41.23
Tax Rate For Calcs
0.00
+3.14%
0.00
+35.85%
0.00
-26.39%
0.00
Tax Effect Of Unusual Items
22.29
+2139.59%
-1.09
-114.58%
7.50
+25.06%
5.99
Net Income Including Noncontrolling Interests
124.45
+3186.63%
-4.03
-107.73%
52.15
+256.33%
-33.36
Net Income From Continuing Operation Net Minority Interest
124.45
+3186.63%
-4.03
-107.49%
53.82
+1131.21%
-5.22
Net Income From Continuing And Discontinued Operation
124.45
+3186.63%
-4.03
-107.73%
52.15
+256.33%
-33.36
Net Income Continuous Operations
124.45
+3186.63%
-4.03
-107.49%
53.82
+1131.21%
-5.22
Net Income Discontinuous Operations
0.00
0.00
+100.00%
-1.67
+94.08%
-28.14
Normalized Income
43.84
+55277.01%
0.08
-99.38%
12.83
+146.20%
-27.77
Net Income Common Stockholders
124.45
+3186.63%
-4.03
-107.73%
52.15
+256.33%
-33.36
Diluted EPS
—
-0.22
-107.48%
2.94
+248.48%
-1.98
Basic EPS
—
-0.22
-107.28%
3.02
+252.53%
-1.98
Basic Average Shares
—
18.29
+5.73%
17.30
+2.55%
16.87
Diluted Average Shares
—
18.29
+3.00%
17.76
+5.27%
16.87
Diluted NI Availto Com Stockholders
124.45
+3186.63%
-4.03
-107.73%
52.15
+256.33%
-33.36
Amortization
32.71
-0.76%
32.96
-2.07%
33.65
-1.70%
34.24
Amortization Of Intangibles Income Statement
32.71
-0.76%
32.96
-2.07%
33.65
-1.70%
34.24
Depreciation Amortization Depletion Income Statement
32.71
-0.76%
32.96
-2.07%
33.65
-1.70%
34.24
Depreciation And Amortization In Income Statement
32.71
-0.76%
32.96
-2.07%
33.65
-1.70%
34.24
Gain On Sale Of PPE
—
—
2.12
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,560.64
+65.71%
941.77
+19.63%
787.22
+3.22%
762.67
Current Assets
832.27
+151.02%
331.56
+39.65%
237.43
-9.93%
263.60
Cash Cash Equivalents And Short Term Investments
756.31
+184.13%
266.19
+56.30%
170.31
-19.62%
211.87
Cash And Cash Equivalents
174.93
+141.92%
72.31
+215.01%
22.95
-49.00%
45.01
Other Short Term Investments
581.39
+199.86%
193.88
+31.58%
147.35
-11.69%
166.86
Receivables
61.05
+43.81%
42.45
+7.98%
39.31
+12.20%
35.04
Accounts Receivable
59.60
+55.31%
38.38
+16.58%
32.92
+8.19%
30.42
Taxes Receivable
1.45
-64.50%
4.07
-36.31%
6.39
+38.60%
4.61
Inventory
9.13
-35.34%
14.11
-41.12%
23.97
+80.30%
13.29
Prepaid Assets
—
1.93
+63.62%
1.18
+4.42%
1.13
Assets Held For Sale Current
—
—
—
0.00
Other Current Assets
5.79
-34.31%
8.81
+231.43%
2.66
+17.20%
2.27
Total Non Current Assets
728.37
+19.36%
610.22
+10.99%
549.79
+10.16%
499.07
Net PPE
10.79
-56.49%
24.81
-1.02%
25.06
-8.84%
27.49
Gross PPE
17.37
-47.48%
33.07
+4.28%
31.72
-15.68%
37.62
Accumulated Depreciation
-6.58
+20.44%
-8.27
-24.24%
-6.66
+34.27%
-10.12
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
5.08
-41.73%
8.72
+12.00%
7.78
-48.66%
15.16
Construction In Progress
0.00
-100.00%
4.22
+2.53%
4.12
—
Other Properties
9.77
+1.04%
9.67
+2.31%
9.46
-37.00%
15.01
Leases
2.52
-75.94%
10.46
+0.97%
10.36
+39.18%
7.45
Goodwill And Other Intangible Assets
326.98
-12.08%
371.90
-7.71%
402.98
-12.07%
458.31
Goodwill
101.54
-3.52%
105.25
+1.82%
103.37
-2.18%
105.67
Other Intangible Assets
225.44
-15.45%
266.65
-11.00%
299.61
-15.04%
352.64
Investments And Advances
364.83
+86.20%
195.93
+75.55%
111.61
+3620.40%
3.00
Long Term Equity Investment
46.50
0.00
-100.00%
12.60
0.00
Other Investments
121.45
+1013.41%
10.91
-70.30%
36.73
—
Non Current Accounts Receivable
—
—
—
—
Non Current Deferred Assets
8.35
+11490.28%
0.07
-66.36%
0.21
-97.49%
8.53
Non Current Deferred Taxes Assets
8.35
+11490.28%
0.07
-66.36%
0.21
-97.49%
8.53
Other Non Current Assets
1.79
-74.18%
6.92
+8.32%
6.39
+268.20%
1.74
Total Liabilities Net Minority Interest
543.42
+388.10%
111.33
+29.00%
86.30
-47.75%
165.18
Current Liabilities
37.45
+0.90%
37.11
+121.14%
16.78
-83.02%
98.81
Payables And Accrued Expenses
28.92
+2.57%
28.20
+193.97%
9.59
-32.30%
14.17
Payables
6.23
-46.25%
11.59
+377.59%
2.43
-54.27%
5.31
Accounts Payable
3.24
-38.12%
5.23
+115.62%
2.43
-54.27%
5.31
Current Accrued Expenses
22.69
+36.66%
16.60
+131.77%
7.16
-19.13%
8.86
Pensionand Other Post Retirement Benefit Plans Current
6.39
+15.68%
5.52
+17.94%
4.68
-24.50%
6.20
Total Tax Payable
2.99
-52.94%
6.36
0.00
—
Income Tax Payable
1.24
+3.34%
1.20
0.00
—
Current Debt And Capital Lease Obligation
1.09
-13.51%
1.27
+208.78%
0.41
-99.47%
77.41
Current Debt
—
—
—
76.69
Other Current Borrowings
—
—
—
76.69
Current Capital Lease Obligation
1.09
-13.51%
1.27
+208.78%
0.41
-42.66%
0.71
Current Deferred Liabilities
0.62
+0.00%
0.62
-66.30%
1.84
+88.83%
0.98
Current Deferred Revenue
0.62
+0.00%
0.62
-66.30%
1.84
+88.83%
0.98
Other Current Liabilities
0.42
-72.02%
1.51
+489.06%
0.26
+349.12%
0.06
Total Non Current Liabilities Net Minority Interest
505.98
+581.70%
74.22
+6.76%
69.52
+4.74%
66.37
Liabilities Heldfor Sale Non Current
—
—
—
0.00
Long Term Debt And Capital Lease Obligation
450.40
+7645.42%
5.82
+1.04%
5.75
-44.32%
10.34
Long Term Debt
446.19
—
—
—
Long Term Capital Lease Obligation
4.20
-27.70%
5.82
+1.04%
5.75
-44.32%
10.34
Tradeand Other Payables Non Current
—
—
14.04
-34.46%
21.42
Non Current Deferred Liabilities
36.02
-28.97%
50.71
+8.43%
46.77
+52.54%
30.66
Non Current Deferred Revenue
0.00
-100.00%
18.18
+20.07%
15.14
+34318.18%
0.04
Non Current Deferred Taxes Liabilities
36.02
+10.75%
32.52
+2.85%
31.62
+3.29%
30.61
Other Non Current Liabilities
19.56
+10.53%
17.70
+4.12%
17.00
-33.01%
25.38
Stockholders Equity
1,017.21
+22.49%
830.44
+18.48%
700.91
+17.31%
597.49
Common Stock Equity
1,017.21
+22.49%
830.44
+18.48%
700.91
+17.31%
597.49
Capital Stock
0.02
+0.00%
0.02
+11.11%
0.02
+5.88%
0.02
Common Stock
0.02
+0.00%
0.02
+11.11%
0.02
+5.88%
0.02
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
19.77
+3.50%
19.11
+8.83%
17.56
+3.57%
16.95
Ordinary Shares Number
19.77
+3.50%
19.11
+8.83%
17.56
+3.57%
16.95
Additional Paid In Capital
400.65
+18.75%
337.38
+69.80%
198.70
+34.63%
147.59
Retained Earnings
608.09
+21.87%
498.98
-0.80%
503.02
+11.57%
450.86
Gains Losses Not Affecting Retained Earnings
8.46
+242.29%
-5.94
-627.29%
-0.82
+16.97%
-0.98
Other Equity Adjustments
8.46
+242.29%
-5.94
-627.29%
-0.82
+16.97%
-0.98
Total Equity Gross Minority Interest
1,017.21
+22.49%
830.44
+18.48%
700.91
+17.31%
597.49
Total Capitalization
1,463.40
+76.22%
830.44
+18.48%
700.91
+17.31%
597.49
Working Capital
794.82
+169.94%
294.45
+33.45%
220.65
+33.90%
164.79
Invested Capital
1,463.40
+76.22%
830.44
+18.48%
700.91
+3.97%
674.18
Total Debt
451.49
+6276.09%
7.08
+14.86%
6.17
-92.97%
87.75
Net Debt
271.26
—
—
31.69
Capital Lease Obligations
5.30
-25.17%
7.08
+14.86%
6.17
-44.21%
11.05
Net Tangible Assets
690.23
+50.53%
458.54
+53.91%
297.94
+114.07%
139.18
Tangible Book Value
690.23
+50.53%
458.54
+53.91%
297.94
+114.07%
139.18
Available For Sale Securities
196.88
+6.41%
185.02
+197.03%
62.29
+1976.37%
3.00
Current Provisions
—
—
—
—
Financial Assets
15.63
+47.71%
10.58
+199.72%
3.53
—
Interest Payable
1.31
0.00
—
—
Investmentin Financial Assets
196.88
+6.41%
185.02
+197.03%
62.29
+1976.37%
3.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
49.36
-49.14%
97.05
+95.75%
49.58
-64.04%
137.85
Cash Flow From Continuing Operating Activities
49.36
-49.14%
97.05
+95.75%
49.58
-64.04%
137.85
Net Income From Continuing Operations
124.45
+3186.63%
-4.03
-107.73%
52.15
+256.33%
-33.36
Depreciation Amortization Depletion
33.77
-4.15%
35.24
-3.51%
36.52
-29.13%
51.53
Depreciation
33.77
-4.15%
35.24
-3.51%
36.52
-29.13%
51.53
Amortization Cash Flow
—
—
-0.88
-435.37%
-0.16
Depreciation And Amortization
33.77
-4.15%
35.24
-3.51%
36.52
-29.13%
51.53
Amortization Of Intangibles
—
—
-0.88
-435.37%
-0.16
Other Non Cash Items
4.84
+30.73%
3.70
-38.73%
6.04
+2.93%
5.87
Stock Based Compensation
46.85
+14.02%
41.09
+59.61%
25.74
-57.30%
60.28
Provisionand Write Offof Assets
—
—
3.60
0.00
Asset Impairment Charge
6.20
-79.73%
30.57
+3208.66%
0.92
0.00
Deferred Tax
22.68
+243.57%
-15.80
-235.09%
11.70
-43.56%
20.72
Deferred Income Tax
22.68
+243.57%
-15.80
-235.09%
11.70
-43.56%
20.72
Operating Gains Losses
-171.82
-1362.40%
-11.75
+75.41%
-47.78
-45.26%
-32.90
Gain Loss On Investment Securities
-19.45
+59.38%
-47.89
-2.74%
-46.62
-63.33%
-28.54
Unrealized Gain Loss On Investment Securities
—
25.79
0.00
0.00
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
-12.66
-165.43%
19.36
+156.26%
-34.40
-152.38%
65.68
Change In Receivables
-21.74
-236.54%
-6.46
-148.33%
-2.60
-104.70%
55.32
Changes In Account Receivables
-21.74
-236.54%
-6.46
-148.33%
-2.60
-104.70%
55.32
Change In Inventory
4.99
-48.14%
9.62
+188.49%
-10.87
-190.15%
12.06
Change In Payables And Accrued Expense
5.88
-57.69%
13.90
+395.56%
-4.70
-40.84%
-3.34
Change In Payable
—
—
-4.70
-40.84%
-3.34
Change In Account Payable
—
—
-4.70
-40.84%
-3.34
Change In Other Working Capital
-1.80
-178.41%
2.29
+114.13%
-16.23
-1089.45%
1.64
Investing Cash Flow
-377.32
-162.64%
-143.66
-1129.79%
-11.68
-107.14%
163.62
Cash Flow From Continuing Investing Activities
-377.32
-162.64%
-143.66
-1129.79%
-11.68
-107.14%
163.62
Net PPE Purchase And Sale
-0.45
+75.18%
-1.82
+48.28%
-3.52
+80.35%
-17.92
Purchase Of PPE
-0.45
+75.18%
-1.82
+48.28%
-3.52
+80.35%
-17.92
Capital Expenditure
-11.31
+42.39%
-19.64
+63.53%
-53.85
-200.45%
-17.92
Net Investment Purchase And Sale
-363.22
-940.07%
43.24
-35.85%
67.40
-63.20%
183.16
Purchase Of Investment
-740.50
-227.10%
-226.38
-78.59%
-126.76
-147.46%
-51.23
Sale Of Investment
377.28
+39.93%
269.62
+38.86%
194.17
-17.16%
234.39
Net Business Purchase And Sale
-8.39
+95.13%
-172.19
-571.20%
-25.65
-3320.53%
-0.75
Purchase Of Business
-8.39
+95.13%
-172.19
-571.20%
-25.65
-3320.53%
-0.75
Gain Loss On Sale Of Business
-53.07
0.00
+100.00%
-2.12
0.00
Net Intangibles Purchase And Sale
-0.60
+94.22%
-10.39
+79.18%
-49.91
-54350.00%
0.09
Purchase Of Intangibles
-10.86
+39.04%
-17.82
+64.59%
-50.33
0.00
Net Other Investing Changes
-4.66
-86.40%
-2.50
—
-0.96
Financing Cash Flow
428.22
+340.83%
97.14
+262.04%
-59.95
+78.28%
-275.99
Cash Flow From Continuing Financing Activities
428.22
+340.83%
97.14
+262.04%
-59.95
+78.28%
-275.99
Net Issuance Payments Of Debt
353.63
+1414632.00%
-0.03
+99.97%
-76.90
+70.54%
-261.00
Issuance Of Debt
466.91
0.00
0.00
—
Repayment Of Debt
-113.28
-453008.00%
-0.03
+99.97%
-76.90
+70.54%
-261.00
Long Term Debt Issuance
466.91
0.00
0.00
—
Long Term Debt Payments
-113.28
-453008.00%
-0.03
+99.97%
-76.90
+70.54%
-261.00
Net Long Term Debt Issuance
353.63
+1414632.00%
-0.03
+99.97%
-76.90
+70.54%
-261.00
Net Common Stock Issuance
-15.00
-140.39%
37.14
0.00
0.00
Common Stock Payments
-15.00
0.00
0.00
0.00
Repurchase Of Capital Stock
-15.00
0.00
0.00
0.00
Proceeds From Stock Option Exercised
114.89
+75.17%
65.59
+192.18%
22.45
+594.55%
3.23
Net Other Financing Charges
-25.30
-354.89%
-5.56
-1.20%
-5.50
+69.83%
-18.22
Effect Of Exchange Rate Changes
2.36
+301.54%
-1.17
0.00
0.00
Beginning Cash Position
72.31
+215.01%
22.95
-49.00%
45.01
+130.54%
19.52
End Cash Position
174.93
+141.92%
72.31
+215.01%
22.95
-49.00%
45.01
Free Cash Flow
38.05
-50.85%
77.41
+1911.96%
-4.27
-103.56%
119.93
Interest Paid Supplemental Data
0.32
+22.05%
0.26
-8.68%
0.29
-79.83%
1.43
Income Tax Paid Supplemental Data
7.80
-59.38%
19.21
+119.00%
8.77
-24.67%
11.64
Amortization Of Securities
-4.96
-272.50%
-1.33
-0.99%
-1.32
-8337.50%
0.02
Common Stock Issuance
0.00
-100.00%
37.14
0.00
0.00
Earnings Losses From Equity Investments
-90.67
-317.91%
41.61
+2174.96%
1.83
0.00
Issuance Of Capital Stock
0.00
-100.00%
37.14
0.00
0.00
Sale Of Business
—
—
—
0.00
Sale Of Intangibles
10.26
+38.12%
7.43
+1677.27%
0.42
+354.35%
0.09
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category